– USA, MA – Corindus Vascular Robotics, Inc. [NYSE: CVRS], a leading developer of precision vascular robotics, today announced that Mark Toland has been appointed Chief Executive Officer and member of the Board of Directors, replacing David Handler who has announced his resignation.
Mr. Toland joins Corindus from Boston Scientific [NYSE: BSX], a global medical technology leader with a significant focus on cardiovascular solutions, where he most recently held the position of Senior Vice President, Corporate Accounts & Global Healthcare Solutions. He brings more than 20 years of operating experience in the cardiovascular medical device industry to Corindus. Mr. Toland spent more than 18 years at Boston Scientific where he led large divisional and corporate teams responsible for U.S. commercial sales and operations across multiple cardiovascular business segments, including Interventional Cardiology, Peripheral, Structural Heart, and Electrophysiology.
“Mark is a highly respected industry veteran with proven leadership skills and an exceptional track record of growing organizations within the interventional cardiovascular industry,” said Jeffrey Lightcap, Chairman of the Board of Directors of Corindus. “Mark’s deep cath lab insights and strategic vision will be instrumental to leading Corindus as we build upon our strong foundation and work to capture the significant potential of robotics in the cath lab.”
Commenting on his appointment, Mark Toland said, “The global opportunity for precision vascular robotics is tremendous. I am extremely impressed with the Company’s skilled team and unique product offering within large segments of the vascular markets. I am excited to join Corindus and look forward to working with the healthcare community on enhancing patient outcomes while reducing radiation exposure and ergonomic strain to physicians and healthcare providers.”
Mr. Lightcap added, “On behalf of the entire Board of Directors and everyone at Corindus, we thank David Handler for his contributions to Corindus which have created a solid foundation for the Company’s future success. Under David’s leadership, Corindus successfully brought the CorPath System through US regulatory approval and its early commercialization. We wish David the best in his future endeavors.”
About Corindus Vascular Robotics, Inc.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company’s CorPath System is the first FDA-cleared medical device to bring robotic-assisted precision to PCI procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded cockpit to advance stents and guidewires with millimeter-by-millimeter precision. The cockpit allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to radial and complex PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual PCI procedures. Corindus stands behind its product with its unique $1,000 hospital credit “One Stent Program.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.